Marjolein Geurts1, Jesper Petersson2, Marco Brizzi2, Stefan Olsson-Hau2, Gert-Jan Luijckx2, Ale Algra2, Diederik W J Dippel2, L Jaap Kappelle2, H Bart van der Worp2. 1. From the Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus (M.G., L.J.K., H.B.v.d.W.) and Julius Center for Health Sciences and Primary Care (A.A.), University Medical Center Utrecht, The Netherlands; Department of Neurology, Skåne University Hospital, Malmö, Sweden (J.P., M.B., S.O.-H.); Department of Neurology, University Medical Center Groningen, The Netherlands (G.-J.L.); and Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands (D.W.J.D.). m.geurts-2@umcutrecht.nl. 2. From the Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus (M.G., L.J.K., H.B.v.d.W.) and Julius Center for Health Sciences and Primary Care (A.A.), University Medical Center Utrecht, The Netherlands; Department of Neurology, Skåne University Hospital, Malmö, Sweden (J.P., M.B., S.O.-H.); Department of Neurology, University Medical Center Groningen, The Netherlands (G.-J.L.); and Department of Neurology, Erasmus University Medical Center, Rotterdam, The Netherlands (D.W.J.D.).
Abstract
BACKGROUND AND PURPOSE: Animal studies suggest that cooling improves outcome after ischemic stroke. We assessed the feasibility and safety of surface cooling to different target temperatures in awake patients with acute ischemic stroke. METHODS: A multicenter, randomized, open, phase II, clinical trial, comparing standard treatment with surface cooling to 34.0°C, 34.5°C, or 35.0°C in awake patients with acute ischemic stroke and an National Institutes of Health Stroke Scale score of ≥6, initiated within 4.5 hours after symptom onset and maintained for 24 hours. The primary outcome was feasibility, defined as the proportion of patients who had successfully completed the assigned treatment. Safety was a secondary outcome. RESULTS: Inclusion was terminated after 22 patients because of slow recruitment. Five patients were randomized to 34.0°C, 6 to 34.5°C, 5 to 35.0°C (cooling was initiated in 4), and 6 to standard care. No (0%), 1 (17%), and 3 (75%) patients, respectively, completed the assigned treatment (P=0.03). No (0%), 2 (33%), and 4 (100%) patients reached the target temperature (P=0.01). Pneumonia occurred in 8 cooled patients but not in controls (absolute risk increase, 53%; 95% confidence interval, 28-79%; P=0.002). CONCLUSIONS: In awake patients with acute ischemic stroke, surface cooling is feasible to 35.0°C, but not to 34.5°C and 34.0°C. Cooling is associated with an increased risk of pneumonia. CLINICAL TRIAL REGISTRATION: URL: http://www.trialregister.nl. Unique identifier: NTR2616.
RCT Entities:
BACKGROUND AND PURPOSE: Animal studies suggest that cooling improves outcome after ischemic stroke. We assessed the feasibility and safety of surface cooling to different target temperatures in awake patients with acute ischemic stroke. METHODS: A multicenter, randomized, open, phase II, clinical trial, comparing standard treatment with surface cooling to 34.0°C, 34.5°C, or 35.0°C in awake patients with acute ischemic stroke and an National Institutes of Health Stroke Scale score of ≥6, initiated within 4.5 hours after symptom onset and maintained for 24 hours. The primary outcome was feasibility, defined as the proportion of patients who had successfully completed the assigned treatment. Safety was a secondary outcome. RESULTS: Inclusion was terminated after 22 patients because of slow recruitment. Five patients were randomized to 34.0°C, 6 to 34.5°C, 5 to 35.0°C (cooling was initiated in 4), and 6 to standard care. No (0%), 1 (17%), and 3 (75%) patients, respectively, completed the assigned treatment (P=0.03). No (0%), 2 (33%), and 4 (100%) patients reached the target temperature (P=0.01). Pneumonia occurred in 8 cooled patients but not in controls (absolute risk increase, 53%; 95% confidence interval, 28-79%; P=0.002). CONCLUSIONS: In awake patients with acute ischemic stroke, surface cooling is feasible to 35.0°C, but not to 34.5°C and 34.0°C. Cooling is associated with an increased risk of pneumonia. CLINICAL TRIAL REGISTRATION: URL: http://www.trialregister.nl. Unique identifier: NTR2616.
Authors: Jason Siegel; Michael A Pizzi; J Brent Peel; David Alejos; Nnenne Mbabuike; Benjamin L Brown; David Hodge; W David Freeman Journal: Curr Cardiol Rep Date: 2017-08 Impact factor: 2.931
Authors: William K Diprose; Catherine A Morgan; Michael Tm Wang; James P Diprose; Joanne C Lin; Sulaiman Sheriff; Doug Campbell; P Alan Barber Journal: J Cereb Blood Flow Metab Date: 2022-06-16 Impact factor: 6.960
Authors: H Bart van der Worp; Malcolm R Macleod; Philip Mw Bath; Raj Bathula; Hanne Christensen; Bridget Colam; Charlotte Cordonnier; Jacques Demotes-Mainard; Isabelle Durand-Zaleski; Christian Gluud; Janus Christian Jakobsen; Bernd Kallmünzer; Rainer Kollmar; Derk W Krieger; Kennedy R Lees; Dominik Michalski; Carlos Molina; Joan Montaner; Risto O Roine; Jesper Petersson; Richard Perry; Nikola Sprigg; Dimitre Staykov; Istvan Szabo; Geert Vanhooren; Joanna M Wardlaw; Per Winkel; Stefan Schwab Journal: Eur Stroke J Date: 2019-04-20
Authors: Paulo Ávila-Gómez; Alba Vieites-Prado; Antonio Dopico-López; Saima Bashir; Héctor Fernández-Susavila; Carme Gubern; María Pérez-Mato; Clara Correa-Paz; Ramón Iglesias-Rey; Tomás Sobrino; Alejandro Bustamante; Sven Wellmann; Joan Montaner; Joaquín Serena; José Castillo; Pablo Hervella; Francisco Campos Journal: Brain Commun Date: 2020-06-04